文献速递浆细胞疾病

多发性骨髓瘤进展受LILRB1调控并通过GATA2-SAGE1通路介导

The progression of multiple myeloma is regulated by LILRB1 via the GATA2-SAGE1 pathway.
PubMed 文献 · Br J Haematol · 2025-05-25

本研究探讨白细胞Ig样受体B亚家族成员1(LILRB1)在多发性骨髓瘤(MM)中的作用及分子机制。结果显示LILRB1在MM患者及细胞系中显著上调、与患者生存负相关;敲低LILRB1促进MM细胞凋亡、增强硼替佐米敏感性并降低皮下小鼠模型致瘤性;机制上LILRB1通过GATA2-SAGE1信号通路维持MM细胞增殖。

要点

  • LILRB1在MM患者及MM细胞系中显著上调,且与患者生存负相关。
  • 敲低LILRB1促进MM细胞凋亡、增强硼替佐米敏感性并降低小鼠致瘤性。
  • LILRB1通过下游GATA2-SAGE1信号通路维持MM细胞增殖。

核心结论

  • LILRB1在多发性骨髓瘤中表达上调并与患者生存负相关,靶向LILRB1可能是有前景的治疗策略。

研究设计与样本

  • 研究检测了MM患者与MM细胞系中LILRB1的表达,并开展敲低实验及皮下小鼠模型实验。

主要发现

  • LILRB1在MM患者和MM细胞系中显著上调,且与患者生存负相关。
  • 敲低LILRB1促进MM细胞凋亡、增强对硼替佐米的敏感性并降低皮下小鼠模型中的致瘤性。
  • LILRB1触发下游GATA2并通过GATA2-SAGE1信号通路维持MM细胞增殖。

临床怎么用

  • 作者认为靶向LILRB1可能代表一种有前景的MM治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a haematological malignancy characterized by the clonal expansion of plasma cells within the bone marrow, thus resulting in the overproduction of monoclonal immunoglobulins. Despite the availability of various immunotherapeutic strategies, patient survival rates remain disappointingly low, thus underscoring the need for innovative immunotherapies to improve outcomes. Leukocyte Ig-like receptor subfamily B (LILRB1), which is a recently identified immune checkpoint, has an undefined role and molecular mechanism in MM. Herein, we demonstrated that LILRB1 was significantly upregulated in MM patients and MM cell lines and was negatively correlated with patient survival. The knockdown of LILRB1 promoted apoptosis in MM cells, enhanced sensitivity to bortezomib and diminished tumourigenicity in a subcutaneous mouse model. Mechanistically, LILRB1 triggers downstream GATA Binding Protein 2 (GATA2) and sustains MM cell proliferation via the GATA2-Sarcoma Antigen 1 (SAGE1) signalling pathway. Consequently, the targeting of LILRB1 may represent a promising therapeutic approach for MM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chen C, Zhou X, Cao L, et al. The progression of multiple myeloma is regulated by LILRB1 via the GATA2-SAGE1 pathway. Br J Haematol. 2025. PMID: 40415416. doi:10.1111/bjh.20144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。